CA3215371A1 - Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome - Google Patents

Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome Download PDF

Info

Publication number
CA3215371A1
CA3215371A1 CA3215371A CA3215371A CA3215371A1 CA 3215371 A1 CA3215371 A1 CA 3215371A1 CA 3215371 A CA3215371 A CA 3215371A CA 3215371 A CA3215371 A CA 3215371A CA 3215371 A1 CA3215371 A1 CA 3215371A1
Authority
CA
Canada
Prior art keywords
sel
patient
sels
natalizumab
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215371A
Other languages
English (en)
French (fr)
Inventor
Shibeshih Mitiku BELACHEW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/024450 external-priority patent/WO2022221297A1/en
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CA3215371A1 publication Critical patent/CA3215371A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3215371A 2021-04-13 2022-04-13 Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome Pending CA3215371A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163174399P 2021-04-13 2021-04-13
FR2103793 2021-04-13
FRFR2103793 2021-04-13
US63/174,399 2021-04-13
US202263320655P 2022-03-16 2022-03-16
US63/320,655 2022-03-16
USPCT/US2022/024450 2022-04-12
PCT/US2022/024450 WO2022221297A1 (en) 2021-04-13 2022-04-12 Methods for classification of lesions and for predicting lesion development
PCT/US2022/024694 WO2022221458A1 (en) 2021-04-13 2022-04-13 Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Publications (1)

Publication Number Publication Date
CA3215371A1 true CA3215371A1 (en) 2022-10-20

Family

ID=81851070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215371A Pending CA3215371A1 (en) 2021-04-13 2022-04-13 Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Country Status (5)

Country Link
EP (1) EP4323407A1 (de)
JP (1) JP2024513974A (de)
AU (1) AU2022259605A1 (de)
CA (1) CA3215371A1 (de)
WO (1) WO2022221458A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512163T1 (de) 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
LT2170390T (lt) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
HRP20230186T1 (hr) 2011-05-31 2023-03-31 Biogen Ma Inc. METODA PROCJENE RIZIKA OD PML-a
EP3004334A4 (de) 2013-05-28 2016-12-21 Biogen Ma Inc Verfahren zur beurteilung eines pml-risikos

Also Published As

Publication number Publication date
AU2022259605A1 (en) 2023-11-02
JP2024513974A (ja) 2024-03-27
WO2022221458A1 (en) 2022-10-20
EP4323407A1 (de) 2024-02-21

Similar Documents

Publication Publication Date Title
Rahmanzadeh et al. Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging
Amoroso et al. Complex networks reveal early MRI markers of Parkinson’s disease
Tur et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Schmidt-Wilcke et al. Diminished white matter integrity in patients with systemic lupus erythematosus
Wang et al. Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease
Calvi et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis
Zhang et al. Characterization of white matter changes along fibers by automated fiber quantification in the early stages of Alzheimer's disease
US20210228079A1 (en) Method for early prediction of neurodegenerative decline
Li et al. Radiomics analysis of magnetic resonance imaging facilitates the identification of preclinical Alzheimer’s disease: an exploratory study
Deng et al. Tractography-based classification in distinguishing patients with first-episode schizophrenia from healthy individuals
Kuchling et al. Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders
Dadar et al. Beware of white matter hyperintensities causing systematic errors in FreeSurfer gray matter segmentations!
Rabasté et al. Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy
Cervo et al. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis
Rajagopalan et al. Differential involvement of corticospinal tract (CST) fibers in UMN-predominant ALS patients with or without CST hyperintensity: A diffusion tensor tractography study
Grydeland et al. Improved prediction of Alzheimer's disease with longitudinal white matter/gray matter contrast changes
Lou et al. Fully automated detection of paramagnetic rims in multiple sclerosis lesions on 3T susceptibility-based MR imaging
Zivadinov et al. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures
Shu et al. An integrative nomogram for identifying early-stage Parkinson's disease using non-motor symptoms and white matter-based radiomics biomarkers from whole-brain MRI
Liu et al. Multi-parametric diffusion tensor imaging of the optic nerve for detection of dysthyroid optic neuropathy in patients with thyroid-associated ophthalmopathy
Münch et al. Segmental alterations of the corpus callosum in motor neuron disease: A DTI and texture analysis in 575 patients
Kaaouana et al. Improved cerebral microbleeds detection using their magnetic signature on T2*-phase-contrast: a comparison study in a clinical setting
Ziccardi et al. Cortical lesions at diagnosis predict long‐term cognitive impairment in multiple sclerosis: A 20‐year study
Chu et al. Comparison of brain microstructure alterations on diffusion kurtosis imaging among Alzheimer’s disease, mild cognitive impairment, and cognitively normal individuals
Wang et al. Association of longitudinal cognitive decline with diffusion MRI in Gray Matter, Amyloid, and Tau deposition